Sugi Predict

Sugi Predict / Compounds / SCHEMBL258501

SCHEMBL258501

SCHEMBL258501

Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 18/20 1.00
▸ MTOR P42345 8/20 1.00
▸ PIK3CG P48736 5/20 0.98
▸ PIK3CB P42338 2/20 0.98
▸ PIK3C2B O00750 1/20 0.98
▸ CCNE2 O96020 1/20 0.98
▸ PRKACA P17612 1/20 0.98
▸ PRKACG P22612 1/20 0.98
▸ PRKACB P22694 1/20 0.98
▸ CCNE1 P24864 1/20 0.98
▸ CDK2 P24941 1/20 0.98
▸ KDR P35968 1/20 0.98
▸ PIK3CD O00329 3/20 0.63
▸ HDAC3 O15379 2/20 0.58
▸ HDAC4 P56524 2/20 0.58
▸ HDAC1 Q13547 2/20 0.58
▸ HDAC7 Q8WUI4 2/20 0.58
▸ HDAC2 Q92769 2/20 0.58
▸ HDAC10 Q969S8 2/20 0.58
▸ HDAC11 Q96DB2 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395747 1.00 PIK3CA (1.00) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL8266691 0.86 PIK3CA (0.76) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22287937 0.86 PIK3CA (0.75) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22315026 0.86 PIK3CA (0.74) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL24885730 0.84 PIK3CA (0.73) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22288063 0.84 PIK3CA (0.72) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22065407 0.84 PIK3CA (0.72) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22287939 0.83 PIK3CA (0.71) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22287941 0.83 PIK3CA (0.71) PIK3CAMTORPIK3CGPIK3CBPIK3C2B
SCHEMBL22287875 0.82 PIK3CA (0.70) PIK3CAMTORPIK3CGPIK3CBPIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 — — EP claimed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US claimed
US-6838457-B2 Fused heteroaryl derivatives YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-04 — — US claimed
US-20040009978-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2004-01-15 — — US claimed
US-20030236271-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2003-12-25 — — US claimed
EP-1277738-A1 CONDENSED HETEROARYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 — — EP claimed
US-20020151544-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2002-10-17 — — US claimed
US-12522614-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2026-01-13 — — US disclosed
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM WAVEBREAK INC (US) 2024-06-27 — — US disclosed
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM WAVEBREAK INC (US) 2024-06-27 — — US disclosed
US-20230416269-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS COA THERAPEUTICS, INC. 2023-12-28 — — US disclosed
EP-4192431-A1 FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS Venthera, Inc. (US) 2023-06-14 — — EP disclosed
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors VENTHERA, INC. (US) 2023-05-30 — — US disclosed
WO-2004017950-A2 PHOSPHADIDYLINOSITOL 3,5-BIPHOSPHATE INHIBITORS AS ANTI-VIRAL AGENTS PIRAMED LIMITED (GB) 2004-03-04 — — WO disclosed
US-20040009978-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2004-01-15 — — US disclosed
US-20030236271-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2003-12-25 — — US disclosed
US-6608056-B1 Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) 2003-08-19 — — US disclosed
US-6608053-B2 Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 — — US disclosed
EP-1277738-A1 CONDENSED HETEROARYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 — — EP disclosed
US-20020151544-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236271-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885MTOR 27/4885PIK3CG 11/4885
US-20040009978-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885MTOR 27/4885PIK3CG 11/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885MTOR 27/4885PIK3CG 11/4885
US-11661429-B2 Topical phosphoinositide 3-kinase inhibitors PIK3C3, PIK3CA, PIK3R1 PIK3CA 2/4885MTOR 97/4885PIK3CG 16/4885
US-20020151544-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A PIK3CA 7/4885MTOR 27/4885PIK3CG 11/4885
US-20230416269-A1 TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS PIK3C3, PIK3CA, PIK3R1 PIK3CA 2/4885MTOR 97/4885PIK3CG 16/4885
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM CPT2, PC, SREBF2 PIK3CA 1288/4885MTOR 426/4885PIK3CG 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.